3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Withdrawn
1
Completed
1
Available
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Uveal Melanoma
1
Select Advanced Solid Tumors
1
Melanoma
1
Interventions
pembrolizumab
62
Nivolumab
40
Ipilimumab
24
trametinib
13
dabrafenib
10
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
binimetinib
9
Cyclophosphamide
8
CTLA-4 Antigen
8
Biopsy
8
encorafenib
7
fludarabine
6
Radiosurgery
6
Cisplatin
6
relatlimab
5
cemiplimab
5
atezolizumab
5
Pemetrexed
5
Introns
5
Interleukin-2
5
tislelizumab
4
lenvatinib
4
fludarabine phosphate
4
durvalumab
4
dostarlimab
4
cobimetinib
4
avelumab
4
Radiotherapy
4
Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Melanoma
×
tebentafusp
×
Clear all
NCT05315258
2025-07-17
TebeMRD
University of Oxford
Phase 2
Active not recruiting
850 enrolled